Indeed, a decrease in MRD can be obtained with the anti-CD33 monoclonal antibody GO in NMP1-mutated AML patients [41] and other favorable ELN-2022 subgroups including core binding factor (CBF) AML [42], especially if administered in two sequential doses. Here, CEBPZ is linked to acute myeloid leukemia.